fbpx

Meet the 2023 PHA Early Career Mentor Scientist Awardee

2023-09-18T17:12:33-04:00September 18th, 2023|

Roopa Siddaiah, MD, FAAP, will receive the 2023 Pulmonary Hypertension Association (PHA) Early Career Mentored Scientist Award. Dr. Siddiah is an associate professor of pediatrics at the Penn State College of Medicine.Dr. Siddaiah’s project, “Predictors of Pulmonary Hypertension Associated Bronchopulmonary Dysplasia,” will explore the early diagnosis of pulmonary hypertension associated with bronchopulmonary dysplasia.

Don’t Miss PHA Live Webinar on Pulmonary Fibrosis-Related PH

2023-09-14T16:37:23-04:00September 14th, 2023|

Join the Pulmonary Hypertension Association at 2 p.m. EDT, today, Thursday, Sept. 14 for the PHA Live webinar, "Understanding the Connection between Idiopathic Pulmonary Fibrosis and PH. Pulmonary fibrosis is a kind of lung disease related to the network of tissue that support air sacs in the lungs. About a third of the people with idiopathic pulmonary fibrosis develop PH. Our speakers, Navneet Singh, MD, MBA, and Christopher King, MD, will give an overview of idiopathic pulmonary fibrosis.

Support Group Forms Book Club

2023-05-11T08:30:08-04:00May 10th, 2023|

The New York City-Manhattan Support Group recently launched a book club to provide new opportunities for people with pulmonary hypertension (PH) to engage online. Leader Alicia Kubes started the support group in 2018 and has been expanding its focus since the pandemic began. The online group aims to discuss books through the lens of living with PH; patients throughout the U.S. are welcome to attend the June 9 meeting.

Prepare Now for Medicaid and CHIP Coverage Changes

2023-03-30T08:58:45-04:00March 29th, 2023|

Take steps to keep you and your family insured in case you’re no longer eligible for pandemic-related health care coverage. During the COVID-19 pandemic, people who no longer were eligible for Medicaid or the Children’s Health Insurance Program (CHIP) could keep their coverage. However, continuous CHIP coverage ends in May, and some states will start to disenroll people from Medicaid on April 1.

Apply for new PHA Research Grant

2023-01-05T09:21:06-05:00January 4th, 2023|

The Pulmonary Hypertension Association is accepting applications for a new grant to support junior pulmonary hypertension researchers. Apply now, or spread the word about PHA’s Early Career Mentored Scientist Award. The one-year grant covers up to $65,000 for PH-related research projects that have been favorably reviewed but not funded by the National Institutes of Health. Apply by March 20.

Important Update for the PH Community Regarding CADD Infusion Systems

2022-12-21T13:18:49-05:00December 19th, 2022|

Specialty pharmacies that distribute pulmonary hypertension (PH) medications are currently reaching out to patients and health care professionals to provide an urgent update about specific lots of CADD infusion systems. If you receive a call or email from your specialty pharmacy about this issue, please respond as soon as possible. PHA is actively monitoring this situation and will provide additional information as it becomes available.

PHA Statement on CADD-MS3 and Subcutaneous Treprostinil for Health Care Professionals

2022-12-19T13:59:12-05:00December 9th, 2022|

Since becoming aware of disruptions in CADD-MS3 (MS3) access earlier this year, the Pulmonary Hypertension Association (PHA) has been meeting with stakeholders and advocating on behalf of health care professionals and patients. To date, PHA has met with ICU Medical (device manufacturer); United Therapeutics Corporation (Remodulin); Liquidia (generic treprostinil); and Accredo Specialty Pharmacy. The

PHA Works to Address CADD MS-3 Pump Shortages

2022-12-19T14:58:34-05:00December 5th, 2022|

Since becoming aware of disruptions in CADD-MS3 access earlier this year, the Pulmonary Hypertension Association (PHA) has been advocating for prompt access to treprostinil. Supply chain disruptions have affected supply of the pump’s LCD screen and slowed the manufacturer’s ability to service pumps for reuse. As a result, specialty pharmacies halted new patient starts on the MS3, and eligible patients may have been shifted to a delivery system for Remodulin.

Title